The purpose of Lertus Retard is to provide systematic supportive relief in managing symptom patterns driven by inflammation, pain, and fever across various medical contexts. The prolonged-release format is applied across domains where additional symptomatic support is needed for managing conditions involving episodic or fluctuating manifestations, which is particularly relevant for long-term conditions.

---

Main Therapeutic Uses and Patient Benefits

Lertus Retard is commonly used across conditions characterized by periods of heightened symptoms, where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, including generalized pain and physical swelling, as well as elevated body temperature, or fever.

The medicine is relevant for inflammatory and degenerative forms of rheumatism, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also applied in scenarios where additional management of discomfort is required for conditions involving episodic or fluctuating manifestations, such as musculoskeletal injuries (including sprains and strains), or symptoms linked to organ-specific functional stress, such as renal colic or primary dysmenorrhea.

It is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.

This approach contributes to easing the overall symptom load and helps maintain a sense of stability during periods where symptoms are more noticeable.

Quick Fact: Relief for Joint Stiffness

Regulatory References

1. Summary of Product Characteristics (HPRA)

Who Can and Cannot Use Lertus Retard?

Eligibility for Lertus Retard (Diclofenac Modified-Release) is strictly governed by population rules detailed in official regulatory documents, such as the Summary of Product Characteristics (SmPC) and FDA labeling. The information below describes population eligibility status and restrictions.

Contraindications and Non-Eligibility

Population Group	Regulatory Status
Pediatric Patients (Under 18 years)	Contraindicated/Not Suited
Third Trimester Pregnancy	Contraindicated
Severe Organ Failure (Hepatic/Renal)	Contraindicated
Severe CV Disease (NYHA II–IV, Ischaemic Heart Disease)	Contraindicated
Active GI Pathology (Ulcers, Bleeding)	Contraindicated

---

Conditional Use and Restrictions

Lertus Retard is primarily allowed for adults (18 years and older) but requires careful consideration or caution in several groups. Treatment for the elderly must begin at the lowest effective dose due to increased risk of serious reactions.

Restricted use applies to:

• Patients with cardiovascular risk factors (e.g., hypertension, diabetes).
• Patients with mild-to-moderate hepatic or renal impairment.
• Patients with Ulcerative Colitis or Crohn's Disease.
• Patients who are nursing mothers or in the first/second trimesters of pregnancy (use is generally not recommended unless essential).

Interactions with other medicines and products

Official regulatory documents categorize the interaction profile of Lertus Retard (Ketoprofen) based on the potential for altered plasma levels or enhanced pharmacological effects when combined with other substances.

Documented Interaction Categories

Category	Description of Official Regulatory Statement
Increased Pharmacodynamic Risk	Co-administration with anticoagulants, antiplatelet agents, and thrombolytics increases the documented risk of bleeding. Combination with corticosteroids increases the officially documented risk of gastrointestinal adverse effects.
Altered Drug Plasma Levels	The product increases the plasma concentration of Lithium and Methotrexate (especially at doses exceeding 15 mg/week) by officially reported mechanisms. Close monitoring is required for these combinations.
Reduced Efficacy	The product can officially reduce the efficacy of Diuretics, ACE inhibitors, Angiotensin II Antagonists, and Beta-blockers, due to effects on renal function.
Additive Toxicity	The risk of nephrotoxicity is documented to increase when combined with Cyclosporine or Tacrolimus, particularly in patients with compromised renal function.

Regulatory Restrictions and Constraints

Concomitant use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including high-dose salicylates, is officially restricted due to the cumulative risk of adverse effects. For Methotrexate at high doses, co-administration is discouraged, and timing-based separation is sometimes required as stated in the product information. Interaction risks are highlighted as being particularly significant in elderly patients and those with impaired renal function.

The Mechanism of Action: Diclofenac

The action of Lertus Retard, containing Diclofenac, is centered on the inhibition of the Cyclooxygenase ( COX) enzyme system. The molecule acts as a preferential inhibitor of the COX-2 enzyme, the inducible protein responsible for the rapid generation of prostaglandins at sites of tissue response. By restricting COX-2 activity, Diclofenac suppresses the conversion of Arachidonic Acid into its precursors, thereby reducing the production of Prostaglandin E2 ( PGE2).

The suppression of PGE2 initiates two defined physiological modulations. Peripherally, it decreases the sensitization of afferent C-fibers, increasing the activation threshold of nociceptors. Centrally, the reduced concentration of PGE2 in the hypothalamus shifts the elevated body temperature set point back toward a homeostatic level. The modified-release formulation ensures a sustained dissolution rate, enabling consistent systemic COX-2 inhibition over an extended period, thus maintaining a stable state of suppressed eicosanoid signaling.

Lertus Retard is formulated as a specialized modified-release tablet and is prescribed for oral administration. The standard adult regimen is a 100 mg strength tablet taken once daily, a frequency pattern directly determined by the prolonged-release design of the formulation. This structural design is engineered to slowly and consistently disperse the active component, Diclofenac Sodium, over an extended period following ingestion.

The structural integrity of the tablet is paramount to maintaining this controlled release mechanism. To ensure this mechanism functions as intended, Lertus Retard must be swallowed whole and must not be crushed, chewed, or divided prior to intake. This critical administration condition ensures the consistent pharmacological profile necessary for its intended daily use pattern. The product may be taken with or without food.

The standard approach for the duration of use is to employ the lowest effective dose for the shortest duration consistent with individual treatment goals. This high-level use pattern is applied even when the medicine is utilized as part of a long-term strategy for chronic inflammatory states. For specific populations, Lertus Retard is designated as not suitable for pediatric patients.

Lertus Retard: Recent Clinical Evidence

---

Study Objective 1: Efficacy in Joint Symptoms

Research has explored whether a therapeutic benefit exists for individuals experiencing active joint symptoms. Research explored the potential action on a key inflammatory pathway.

• Key Findings:
  • Studies examined whether the treatment is associated with a reduction in joint pain. Findings varied, with some trials reporting an observation in pain scores compared to placebo, while others did not.
  • Research evaluated whether a sustained reduction in flare-ups occurred over a 6-month period. Data suggests that in some patient cohorts, the frequency of flare-ups was observed to be lower.

---

Study Objective 2: Long-Term Disease Management

Research has focused on the long-term impact of the treatment. Large-scale studies primarily aimed to track patient outcomes over several years to understand the progression of the condition while on the treatment.

• Assessment in Refractory Cases:
  • Studies assessed outcomes in refractory cases, which are individuals who did not respond adequately to prior therapies. These investigations generally focused on changes in disease activity measures over a 12-month period.
• Combination Therapy Evaluations:
  • The role of this therapy as a first-line option has been investigated, though evidence remains limited.
  • Studies evaluated whether this combination of treatments was associated with improved patient quality of life compared to standard care, using validated patient questionnaires. A large-scale study examined these findings further.

---

Study Objective 3: Safety and Tolerability Profile

Research has investigated whether treatment minimizes long-term damage related to the condition. Investigators monitored for adverse events and laboratory abnormalities throughout all trials.

• Observed Side Effects:
  • The most commonly observed events included mild injection site reactions and upper respiratory tract infections. The rate of serious infections was monitored across all phases of research.
• Discontinuation Rates:
  • Across studies, the percentage of participants who discontinued the treatment due to adverse events was consistently reported. This data provides information regarding the general tolerability profile.

Common questions about Lertus Retard (FAQ)

---

Q: Is Lertus Retard a painkiller or something else?

A: Lertus Retard contains the active ingredient Diclofenac, which is classified as a nonsteroidal anti-inflammatory drug (NSAID). Official regulatory documents indicate that it possesses analgesic (painkilling), anti-inflammatory, and antipyretic (fever-reducing) properties.

---

Q: Does Lertus Retard have any narcotic properties?

A: No. The active ingredient, Diclofenac, is classified as an NSAID. The substance is not listed as an opioid or narcotic, and it works by reducing inflammation and pain through the inhibition of prostaglandins.

---

Q: Is it normal to feel drowsy after taking Lertus Retard?

A: Official product information lists dizziness as a common side effect and somnolence (drowsiness) as a rare side effect. If these effects are experienced, regulatory guidance advises caution regarding driving or operating heavy machinery.

---

Q: Can Lertus Retard cause stomach upset or digestive issues?

A: Yes, gastrointestinal (GI) disturbances are commonly reported in official regulatory documents. These can include nausea, vomiting, diarrhea, abdominal pain, and dyspepsia (indigestion). Serious GI risks, such as bleeding, are also noted in the product warnings.

---

Q: Will taking Lertus Retard affect my ability to drive?

A: Regulatory guidance advises avoiding driving or operating machinery if side effects like dizziness, somnolence (drowsiness), or other disturbances of the central nervous system occur. This is because these effects could impair judgment and physical ability.

---

Q: Is Lertus Retard commonly used for chronic vs. acute conditions?

A: Official labeling indicates the medication is approved for managing symptoms of chronic inflammatory conditions, such as osteoarthritis. It is also approved for certain acute pain conditions, including painful menstrual cramps.

---

Q: What should I do if I miss a dose of Lertus Retard?

A: Lertus Retard is a modified-release formulation intended for once-daily use. Regulatory sources generally suggest that if a dose is missed and it is almost time for the next scheduled dose, the missed dose should be skipped to avoid taking a double dose.

---

Q: Why do some people say Lertus Retard causes vivid dreams?

A: While not common, nightmares are listed in official regulatory documents as a very rare potential side effect, grouped under psychiatric disorders. these unusual experiences should be reported to a healthcare provider if they persist.

---

Q: Are there any less common but serious side effects I should be aware of?

A: Yes, regulatory warnings highlight the potential for serious risks. These include serious cardiovascular events (such as heart attack or stroke), severe gastrointestinal bleeding or ulceration, and rare instances of severe liver or kidney damage.

---

Q: Is it okay to drink alcohol while on Lertus Retard?

A: Official product information advises caution. Combining alcohol with this type of NSAID medication is documented to increase the risk of serious gastrointestinal adverse effects, including bleeding. The decision to consume alcohol while using this medication should be made in consultation with a healthcare provider.

---

Q: Is there a generic version of Lertus Retard available?

A: Yes, the active ingredient in its extended-release form, diclofenac sodium extended-release tablets, is generally available. Regulatory bodies classify these generic products as bioequivalent to the branded formulation.

---

Q: Does Lertus Retard build up in the body over time?

A: Official pharmacokinetic data indicates that the active ingredient has a short elimination half-life, meaning it is quickly cleared. Regulatory studies indicate there is generally no significant accumulation of the unchanged drug in the bloodstream after repeated administration.

---

Q: Can Lertus Retard cause changes in mood or anxiety?

A: Changes in mood, such as anxiety, depression, and irritability, are listed in regulatory documents as very rare adverse reactions. Mood-related changes should be reported to a healthcare professional if they occur.

---

Q: Has Lertus Retard been subject to any recent safety warnings?

A: The official labeling carries continuous safety warnings regarding the risks of serious cardiovascular and gastrointestinal events. These warnings are highlighted in the product information to inform patients and professionals of potential risks.

---

Q: Is it normal to have minor headaches when starting Lertus Retard?

A: Headache is listed in official regulatory documents as a common side effect of the active ingredient. It is a frequent complaint, especially when treatment is first initiated.

---

Q: Are there any lifestyle changes recommended while taking Lertus Retard?

A: Regulatory warnings imply the need for caution concerning certain activities. This includes restricting or avoiding alcohol intake due to the increased risk of gastrointestinal bleeding, and being careful with activities like driving if side effects like dizziness occur.

---

Q: What is the significance of the strength (e.g., 100mg) of Lertus Retard?

A: The 100 mg strength is the approved dose for the extended-release formulation. This dose is designed to provide a stable, sustained effect over an extended period to help manage chronic inflammatory states.

---

Q: How soon after stopping Lertus Retard can I take a different medication?

A: The half-life of the active ingredient is approximately two hours. While the drug is quickly cleared from the plasma, the decision to start a new medication after stopping should be made in consultation with a healthcare professional.

---

Q: Does Lertus Retard cause weight gain or weight loss?

A: Generalized weight changes are not specifically listed, but oedema (fluid retention or swelling) is noted as a rare potential side effect. Fluid retention should be brought to the attention of a healthcare professional.

---

Q: Is Lertus Retard used in the treatment of migraines?

A: Official regulatory documents confirm that specific formulations of the active ingredient, diclofenac, are approved for the acute treatment of migraine attacks in adults.

---

Q: Can Lertus Retard affect sleep patterns?

A: Yes, official product information lists insomnia (difficulty sleeping) as a very rare adverse effect. Changes in sleep patterns should be reported to a healthcare provider if they occur.

---

Q: What kind of research supports the use of Lertus Retard?

A: Regulatory approval is based on clinical trials that demonstrate the efficacy of the active ingredient in managing pain and inflammation. The component, Diclofenac, is widely recognized as an essential NSAID by major health organizations.

---

Q: What is the shelf life or how should Lertus Retard be stored?

A: Official documents require that the product must not be used after the expiration date. To maintain quality, it must be stored under specific conditions, typically not exceeding 30 C and protected from light.

---

Q: Is there a specific mechanism by which Lertus Retard relieves symptoms?

A: Yes. The mechanism, as detailed in regulatory documents, involves the non-selective inhibition of the Cyclooxygenase (COX) enzyme system. This process reduces the body's production of prostaglandins, which are key chemical mediators of pain and inflammation.

How to Store and Dispose of Lertus Retard

Storage and disposal of Lertus Retard (Diclofenac Sodium 100 mg prolonged-release tablets) must strictly adhere to the requirements stated in official regulatory documents to maintain product quality and safety.

Official Storage Constraints

Constraint Type	Requirement
Temperature	Store at a temperature not exceeding 30 C or 25 C (depending on license).
Protection	Must be protected from light.
Container	Keep in its original container; do not use if packaging is damaged.
Safety	Mandatory to store out of the reach of children.

Disposal Guidance

Use of the product is prohibited after the expiration date. Disposal of any unused or expired Lertus Retard must be performed in accordance with local requirements. The medicine should not be repeated or recommended to others without medical guidance.